Psyence Biomedical (PBM) Gains from Investment Securities (2024 - 2025)

Psyence Biomedical's (PBM) quarterly Gains from Investment Securities came in at -$58016.0 in Q3 2025, down 3557.45% year-on-year from $1678.0 in Q3 2024, and down 3557.45% quarter-over-quarter from $1678.0 in Q3 2024.

Psyence Biomedical (PBM) Gains from Investment Securities (2024 - 2025) Analysis & Trends

Psyence Biomedical's Gains from Investment Securities history runs 2 years deep, the most recent figure standing at -$58016.0 for Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn -
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn
7 Belite Bio 62.72 Bn 62.72 Bn -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn
9 Revolution Medicines 37.35 Bn 37.35 Bn -
10 Psyence Biomedical 1.66 Mn 1.66 Mn -

Historic Data

Download Data
DateValue
Sep 30, 2025 -58,016.00
Sep 30, 2025 -58,016.00
Sep 30, 2024 1,678.00
Sep 30, 2024 1,678.00